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Four year efficacy of prophylactic human papillomavirus
quadrivalent vaccine against low grade cervical, vulvar, and
vaginal intraepithelial neoplasia and anogenital warts:
randomised controlled trial
The FUTURE I/II Study Group
ABSTRACT
Objectives To evaluate the prophylactic efficacy of the
human papillomavirus (HPV) quadrivalent vaccine in
preventing low grade cervical, vulvar, and vaginal
intraepithelial neoplasias and anogenital warts
(condyloma acuminata).
Design Data from two international, double blind,
placebo controlled, randomised efficacy trials of
quadrivalent HPV vaccine (protocol 013 (FUTURE I) and
protocol 015 (FUTURE II)). The trials were to be 4 years in
length, and the results reported are from final study data
of 42 months’ follow-up.
Setting Primary care centres and university or hospital
associated health centres in 24 countries and territories
around the world.
Participants 17622 women aged 16-26 years enrolled
between December 2001 and May 2003. Major exclusion
criteria were lifetime number of sexual partners (>4),
history of abnormal cervical smear test results, and
pregnancy.
Intervention Three doses of quadrivalent HPV vaccine (for
serotypes 6, 11, 16, and 18) or placebo at day 1,month 2,
and month 6.
Main outcome measures Vaccine efficacy against
cervical, vulvar, and vaginal intraepithelial neoplasia
grade I and condyloma in a per protocol susceptible
population that included subjects who received all three
vaccine doses, tested negative for the relevant vaccine
HPV types at day 1 and remained negative throughmonth
7, and had nomajor protocol violations. Intention to treat,
generally HPV naive, and unrestricted susceptible
populations were also studied.
Results In the per protocol susceptible population,
vaccine efficacy against lesions related to the HPV types
in the vaccine was 96% for cervical intraepithelial
neoplasia grade I (95% confidence interval 91% to 98%),
100% for both vulvar and vaginal intraepithelial
neoplasia grade I (95% CIs 74% to 100%, 64% to 100%
respectively), and 99% for condyloma (96% to 100%).
Vaccine efficacy against any lesion (regardless of HPV
type) in the generally naive population was 30% (17% to
41%), 75% (22% to 94%), and 48% (10% to 71%) for
cervical, vulvar, and vaginal intraepithelial neoplasia
grade I, respectively, and 83% (74% to 89%) for
condyloma.
Conclusions Quadrivalent HPV vaccine provided
sustained protection against low grade lesions
attributable to vaccineHPV types (6, 11, 16, and18) and a
substantial reduction in the burden of these diseases
through 42 months of follow-up.
Trial registrations NCT00092521 and NCT00092534.
INTRODUCTION
Human papillomaviruses (HPVs) are responsible for
about 500 000 cases of cervical cancer a year
globally1 and 10 million further cases of high grade
cervical intraepithelial neoplasias (grades II or III),2
immediate precursors to malignancy. It is estimated
that 30 million women and men acquire anogenital
warts (condyloma acuminata) or low grade cervical
intraepithelial neoplasia each year,2 which may be an
underestimation given the inadequacy of reporting in
many countries and evidence of a rising incidence over
time. Although many low grade lesions of the lower
genital tract resolve spontaneously in immunocompe-
tent subjects, this type of lesion contributes greatly to
the clinical and economic burden of HPV disease in
women. The psychosocial3 4 and economic56 implica-
tions of condyloma are substantial and reflect, in part,
the high transmission rates and inadequacyof available
treatment options in achieving prolonged response
rates.7-9 Cervical intraepithelial neoplasia grade I can
contain a variety of low or high risk HPV types,10-12
whereas anogenital warts are (in up to 90% of cases)
caused by either of two low risk HPV types—namely,
6 and 11.9 13 14
The quadrivalent HPV vaccine (for types 6, 11, 16,
and 18) has the potential to prevent about 70% of cer-
vical cancers15 and 90% of condyloma913 by targeting
HPV types 16 and 18 and types 6 and 11, respectively.
Clinical trials have shown that in the per protocol
population (that is, subjects naive to a given HPV
type(s) at baseline and throughout the three dose vac-
cination) vaccine efficacy against cervical intra-
epithelial neoplasia grade II-III or adenocarcinoma
in situ was 99% (95% confidence interval 93% to
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100%).16 Efficacy against vulvar and vaginal intra-
epithelial neoplasia grade II-III was 100% (72% to
100%).17 High efficacy against condyloma has also
been demonstrated (100% (92% to 100%)).18 These
data have led to regulatory approval of the vaccine in
roughly 100 countries for the prevention of cervical
cancer, cervical cancer precursor lesions, and condy-
loma in girls and women aged 9-26 years. In some
countries, the approved indication also includes vulvar
and vaginal cancers.
The contribution of HPV types 6, 11, 16, and 18 to
low grade neoplasias has not beenwell elucidated. The
HPV types have been found in 25-50% of low grade
cervical and vulvovaginal neoplasias,10-12 but assigning
causality is difficult because most of these lesions con-
tainmultipleHPV types.Whether elimination of some
of the HPV types in a multiple infection will prevent
disease can be proved only through vaccination. This
report represents a combined analysis of quadrivalent
HPV vaccine protocols 013 (FUTURE I trial) and 015
(FUTURE II trial), focusing on the efficacy of the vac-
cine in preventing low grade cervical and vulvovaginal
lesions (grade I neoplasias and condyloma) after an
average of 42 months of follow-up. We also sought to
describe the proportion of the low grade disease bur-
den that can be prevented by vaccination against HPV
types 6, 11, 16, and 18.
METHODS
Study designs
Data are considered from two international, double
blind, placebo controlled, randomised efficacy trials
of the quadrivalent HPV vaccine (protocol 01318
(FUTURE I, NCT00092521) and protocol 01519
(FUTURE II, NCT00092534)). These trials were simi-
lar in design and infrastructure and were conducted
among women aged 16-26 years fromNorth America,
Latin America, Europe, and Asia Pacific. Primary effi-
cacy end points assessed in protocol 013 included (a)
condyloma, vulvar and vaginal intraepithelial neopla-
sia, or vulvar and vaginal cancer related to HPV types
6, 11, 16, or 18; and (b) cervical intraepithelial neopla-
sia, adenocarcinoma in situ, or cervical cancer related
toHPV types 6, 11, 16, or 18. The primary efficacy end
points assessed in protocol 015 were cervical intra-
epithelial neoplasia grades II-III and cervical cancer
related to HPV types 16 or 18.
Pregnant women and those with a history of >4 life-
time sexual partners or history of an abnormal cervical
smear test result were not eligible to participate in these
trials. The institutional review board at each participat-
ing centre approved the protocol, and informed con-
sent was obtained from all participants. The current
report details the complete follow-up data from proto-
cols 013 and 015, representing a mean follow-up per-
iod of 42 months.
Vaccine
In each of the studies, eligible subjectswere randomised
in a 1:1 ratio to receive three doses of the quadrivalent
(HPV types 6, 11, 16, and 18) LI virus-like particle vac-
cine (Gardasil,Merck,Whitehouse Station,NJ,USA) or
placebo at day 1,month 2, andmonth 6 (additional vac-
cination regimens included as part of protocol 013 did
not contribute to the data reported here).
Study procedures
Detailed cervicovaginal examinationswere performed
at the scheduled day 1 and month 7 visits, including
cervical collections for cervical smear testing (Thin-
Prep, Cytyc Corporation, Boxborough, MA, USA),
Details of different patient populations analysed for efficacy of quadrivalent human
papillomavirus (HPV) vaccine
Per protocol susceptible population
 Subjects
Received all three vaccination doses
Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and polymerase
chain reaction (PCR)) and through month 7 (by PCR)
Generally did not deviate from study protocol
 Case counting began after month 7
 Represents an ideal population under ideal study conditions and approximates to a
sexually naive population
 Used for analyses of disease related to HPV types 6, 11, 16, and 18
Unrestricted susceptible population
 Subjects
Received ≥1 vaccination dose
Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and PCR)
Had any follow-up visit
 Case counting began after day 1
 Represents a broader population than per protocol susceptible population, including
subjects completing the full three vaccination doses and others who received only one
or two doses
 Used for analyses of disease related to HPV types 6, 11, 16, and 18
Generally HPV naive population
 Subjects
Received ≥1 vaccination
Were negative for HPV types 6, 11, 16, and 18 at day 1 (by serology and PCR), negative
at day 1 for other high risk HPV types with PCR assays available (31, 33, 35, 39, 45, 51,
52, 56, 58, and 59), and had a negative cervical smear test result on day 1
Had any follow-up visit
 Case counting began after day 1
 Represents an approximation of a “real world” population of HPV naive women
 Used for analyses of disease due to any HPV type
Intention to treat population
 Subjects
Received ≥1 vaccination
Had any follow-up visit (>98% of all subjects enrolled)
 Case counting began after day 1
 Represents a population of women with past and current HPV exposures as well as
those presumably naive to HPV
 Used for analyses of disease related to
HPV types 6, 11, 16, and 18
Any HPV type
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comprehensive anogenital inspection, and a series of
cervical or anogenital swab collections (that is, endo-
cervical or ectocervical, combined labial-vulvar-peri-
neal, and perianal swabs) for HPV DNA testing.
Protocol 013 had an additional scheduled visit at
month 3, during which gynaecological examination
and cervical or anogenital swab collection occurred
(but not serum sampling or cervical smear testing).
Cytology specimens were evaluated using the 2001
Bethesda system.20 Colposcopy referral was based on
a decision algorithm. Biopsy material was first read for
clinical management by pathologists at a central
laboratory (Diagnostic Cytology Laboratories, India-
napolis, IN) and then read for end point determination
by a blinded panel of four pathologists.
After the three dose vaccination, protocol 013 parti-
cipants were to return for follow-up assessments every
sixmonths (untilmonth 48), whereas protocol 015 par-
ticipants were seen every 12 months (until month 48).
Interim visits were required six months after detection
of atypical squamous cells of undetermined signifi-
cance or low grade squamous intraepithelial lesions
to provide the opportunity for repeat cervical smear
testing and, if indicated, further colposcopic evaluation
and biopsy. If an anogenital lesion was detected, inves-
tigators were instructed to obtain specimens represent-
ing each affected area and each morphology in a given
area.Definitive treatmentwas based on local standards
of care.
Sensitive and specific multiplex polymerase chain
reaction assayswere used forHPV typingof biopsy sam-
ples for HPV 6, 11, 16, 18, and 10 other HPV types (31,
33, 35, 39, 45, 51, 52, 56, 58, and 59). For the low grade
analyses reportedhere, a case required a consensus diag-
nosis from the pathology panel of cervical, vaginal, or
vulvar intraepithelial neoplasia grade I, or condyloma
with DNA of HPV types 6, 11, 16, or 18 detected in an
adjacent section from the same tissue block.
In 2005 the International Society for the Study of
Vulvovaginal Disease changed nomenclature for vul-
var intraepithelial neoplasia and categorised it as usual
(u-VIN, HPV related) or differentiated (d-VIN, not
HPV related) types. The term VIN I was abandoned,
and terms VIN II and VIN III were merged.21 In this
report, however, we have maintained the original
nomenclature (VIN I) that was used by the pathology
panel during the course of the studies.
Statistical methods
The box lists the criteria and rationale for the analysis
populations considered in this report (per protocol sus-
ceptible, intention to treat, generally HPV naive, and
unrestricted susceptible). The statistical analysis plan
specified that determination of the efficacy of the vac-
cine was to be based on analyses of the per protocol
susceptible population; other populations were ana-
lysed only for supportive results.
Vaccine efficacy analyses were performed based on
low grade lesion type, pooling subjects across the stu-
dies by vaccination group (vaccine or placebo). Data
were analysed to determine vaccine efficacy against
lesions attributable to vaccine HPV types (6, 11, 16,
and 18) as well as to any tested HPV type, with the
latter analyses including the 10 non-vaccine HPV
types for which polymerase chain reaction testing was
performed in protocols 013 and 015 (types 31, 33, 35,
Table 1 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18):
analysis of per protocol susceptible population*
Lesion and related HPV type†
Vaccine group Placebo group Vaccine efficacy (% (95% CI))
No of cases/
No of subjects
Person
years at risk
No of cases/
No of subjects
Person
years at risk Unadjusted Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 7/7629 22 456.6 168/7632 22 306.3 95.9 (91.3 to 98.4) 95.9 (91.2 to 98.1)
HPV 6 or 11 0/6688 19 756.5 45/6619 19 452.6 100 (91.6 to 100) 100 (NA)
HPV 16 6/6448 19 122.2 97/6257 18 531.1 94.0 (86.5 to 97.9) 93.9 (86.2 to 97.3)
HPV 18 1/7158 21 118.9 47/7092 20 827.4 97.9 (87.7 to 99.9) 97.9 (84.8 to 99.7)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 0/7665 23 042.9 16/7669 23 041.1 100 (74.1 to 100) 100 (NA)
HPV 6 or 11 0/6718 20 179.0 16/6647 19 982.8 100 (74.3 to 100) 100 (NA)
HPV 16 0/6455 19 417.0 0/6269 18 859.6 NA NA
HPV 18 0/7190 21 613.9 0/7119 21 418.9 NA NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 0/7665 23 042.9 12/7669 23 049.8 100 (64.0 to 100) 100 (NA)
HPV 6 or 11 0/6718 20 179.0 6/6647 19 999.0 100 (15.8 to 100) 100 (NA)
HPV 16 0/6455 19 417.0 7/6269 18 859.6 100 (32.6 to 100) 100 (NA)
HPV 18 0/7190 21 613.9 2/7119 21 418.9 100 (<0 to 100) 100 (NA)
Condyloma (HPV 6, 11, 16, 18): 2/7665 23 039.6 190/7669 22 849.4 99.0 (96.2 to 99.9) 99.0 (95.8 to 99.7)
HPV 6 or 11 2/6718 20 175.7 186/6647 19 798.0 98.9 (96.1 to 99.9) 98.9 (95.7 to 99.7)
HPV 16 0/6455 19 417.0 23/6269 18 839.4 100 (83.1 to 100) 100 (NA)
HPV 18 0/7190 21 613.9 11/7119 21 406.8 100 (60.5 to 100) 100 (NA)
*Per protocol susceptible population=subjects who (a) received all three vaccinations; (b) tested negative for vaccine HPV types at day 1 (by serology and polymerase chain reaction (PCR))
and through month 7 (by PCR); and (c) generally did not deviate from the protocol. Case counting began after month 7.
†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the
absence of an abnormal cervical smear test result at the antecedent visit were excluded.
‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.
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39, 45, 51, 52, 56, 58, and 59). Unadjusted vaccine effi-
cacy rates were calculated as (1−relative risk)×100,
with corresponding 95% confidence intervals esti-
mated via an exact conditional procedure.22 Relative
risk was defined as the ratio of the incidence rate in
the vaccine group divided by the incidence rate in the
placebo group, using person-time incidence rates.
In order to adjust for study effect and country effect,
vaccine efficacy rates were also calculated using a Cox
model in which protocol and region were included as
cofactors. Regarding themethod used for adjusting for
study effect and region, we settled for using a Cox
regression model because it is more distribution-free
(semi-parametric) than Poisson regression. When cal-
culating the vaccine efficacy as 1−relative risk (that is,
1−hazard ratio, with the Coxmodel), the only assump-
tion used was that the ratio of hazards is constant over
time (but the underlying risks can vary over time). An
alternative analysis with Poisson regression (using the
PROC GENMOD procedure in the SAS statistical
package) gave almost identical results (supplementary
table A on bmj.com).
Many of the efficacy end points analysed here and in
previous reports are composite, capturing more than
one pathological diagnosis or more than one HPV
type, or both. Subjects were counted as a single case
for a composite end point regardless of whether they
met the criteria for only one or for more of its compo-
nents; however, individual subjects were counted
within each of the individual components for which
the criteria were met. For example, a subject with both
HPV type 6 and type 16 identified in an emergent ano-
genitalwartwas countedoncewithin eachHPV-specific
analysis but only once in the composite end point of
condyloma related to HPV types 6, 11, 16, or 18.
RESULTS
Subject population
A total of 17 599 women aged 16-26 years were rando-
mised and received one or more dose of the quadriva-
lent HPV vaccine or placebo. Baseline characteristics
for the randomised population, which were similar in
the vaccine and placebo groups, have been published
previously.23 Overall, mean age at enrolment was
20.0 years, mean age at first sexual intercourse was
16.7 years, non-virgins had a mean of 2.1 lifetime sex-
ual partners, and 11.2% of subjects (1955/17 433) had
abnormal cervical cytology at enrolment. The day 1
prevalence for one or more of the HPV types included
in the vaccinewas 14.7%by polymerase chain reaction
(2593/17622) and 19.8% by serology (3482/17 581). A
day 1 positive test forDNAofHPV types 6, 11, 16, and
18 was 4.1% (717/17 622), 0.7% (120/17 622), 8.7%
(1553/17 622), and 3.6% (641/17 622), respectively.
Corresponding day 1 seropositivity was 8.2% (1438/
17 567), 2.0% (1036/17 566), 11.3% (1980/17 567),
and 3.7% (646/17 566), respectively.
Efficacy in preventing disease related to HPV types 6, 11,
16, or 18
As expected, compared with the per protocol suscep-
tible population (table 1), more cases of low grade
cervical or vulvar intraepithelial neoplasia and condy-
loma were documented in the unrestricted susceptible
and intention to treat populations (tables 2 and 3,
respectively). Vaccine efficacy in the intention to
Table 2 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18):
analysis of unrestricted susceptible population*
Lesion and related HPV type†
Vaccine group Placebo group Vaccine efficacy (% (95% CI))
No of cases/
No of subjects
Person
years at risk
No of cases/
No of subjects
Person
years at risk Unadjusted Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 12/8375 29 081.4 235/8430 29 063.8 94.9 (90.9 to 97.4) 94.9 (90.8 to 97.1)
HPV 6 or 11 2/7420 25 879.5 60/7466 25 870.6 96.7 (87.4 to 99.6) 96.6 (86.2 to 99.2)
HPV 16 6/7113 24 979.5 137/7141 24 944.4 95.6 (90.2 to 98.4) 95.6 (90.1 to 98.1)
HPV 18 4/7906 27 537.1 66/7970 27 622.0 93.9 (83.7 to 98.4) 93.9 (83.4 to 97.8)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 2/8497 29 825.1 20/8532 29 995.6 89.9 (58.6 to 98.9) 89.9 (57.0 to 97.6)
HPV 6 or 11 2/7529 26 429.1 18/7553 26 582.1 88.8 (53.3 to 98.7) 88.8 (51.7 to 97.4)
HPV 16 0/7220 25 363.4 2/7222 25 444.7 100 (<0 to 100) 100 (NA)
HPV 18 0/8022 28 179.3 0/8067 28 387.4 NA NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 0/8497 29 829.3 18/8532 30 000.6 100 (77.1 to 100) 100 (NA)
HPV 6 or 11 0/7529 26 433.3 7/7553 26 600.8 100 (30.2 to 100) 100 (NA)
HPV 16 0/7220 25 363.4 10/7222 25 436.7 100 (55.3 to 100) 100 (NA)
HPV 18 0/8022 28 179.3 5/8067 28 387.4 100 (<0 to 100) 100 (NA)
Condyloma (HPV 6, 11, 16, 18): 10/8497 29 807.5 249/8532 29 692.7 96.0 (92.5 to 98.1) 96.0§ (92.5 to 97.9)
HPV 6 or 11 9/7529 26 414.0 243/7553 26 287.7 96.3 (92.9 to 98.3) 96.3 (92.8 to 98.1)
HPV 16 1/7220 25 360.9 27/7222 25 411.6 96.3 (77.5 to 99.9) 96.2 (72.3 to 99.5)
HPV 18 0/8022 28 179.3 19/8067 28 364.7 100 (78.4 to 100) 100 (NA)
*Unrestricted susceptible population=subjects who (a) received ≥1 vaccination; (b) tested negative for vaccine HPV types at day 1 (by serology and polymerase chain reaction); and (c) had
any follow-up visit. Case counting began after day 1.
†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the
absence of an abnormal cervical smear test result at the antecedent visit were excluded.
‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.
§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.
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treat and unrestricted susceptible populations was gen-
erally lower than observed in the per protocol suscep-
tible population, but it remained statistically significant
for all four disease end points, ranging from 90% for
vulvar intraepithelial neoplasia (2 cases in vaccine
group v 20 cases in placebo group) to 100% for vaginal
intraepithelial neoplasia (0 v 18 cases) in the unrest-
ricted susceptible population (table 2) and from 69%
for cervical intraepithelial neoplasia (114 v 366 cases)
to 83% for vaginal intraepithelial neoplasia (4 v 24
cases) in the intention to treat population (table 3).
Reductions were also seen in both populations when
we evaluated vaccine efficacy against lesions attributa-
ble to specific vaccine HPV types (tables 2 and 3).
In the per protocol susceptible population (table 1),
seven cases of cervical intraepithelial neoplasia attribu-
table toHPV types 6, 11, 16, or 18were documented in
the vaccine group (n=7629) after month 7 compared
with 168 cases in the placebo group (n=7632)—trans-
lating into a vaccine efficacy of 96% (95% confidence
interval 91% to 98%). Stratified by HPV type, vaccine
efficacy rates against cervical intraepithelial neoplasia
remained statistically significant and ranged from 94%
forHPV16 to 100% forHPV6or 11 (table 1).With no
cases of vulvar or vaginal intraepithelial neoplasia attri-
butable to vaccine HPV types (6, 11, 16, or 18) in the
vaccine group compared with 16 cases and 12 cases,
respectively, in the placebo group (n=7669), vaccine
efficacy was 100% in preventing these low grade neo-
plasias. All of the emergent vulvar cases in the placebo
group were attributable to HPV types 6 or 11, whereas
all four vaccine HPV types were identified among the
vaginal lesions. There were two cases of condyloma
attributable to vaccineHPV types among vaccine reci-
pients (n=7665) versus 190 cases among placebo reci-
pients (n=7669)—a vaccine efficacy of 99% (96% to
100%). HPV type 6 was documented in both of the
cases of condyloma in the vaccine group, and HPV
types 6 or 11 were found in 98% of the placebo cases
(186/190). Table 4 summarises the cases of lesions
attributable to vaccineHPV types among vaccine reci-
pients in the per protocol susceptible population.
Efficacy in preventing disease due to any HPV type
Vaccine efficacy against any cervical intraepithelial
neoplasia grade I (regardless of HPV types present)
was 30% (17% to 41%) in the generally HPV naive
population (241 cases in vaccine group v 346 in pla-
cebo group) and 20% (12% to 28%) in the intention to
treat population (788 v 984 cases) (table 5). In the gen-
erally HPV naive population, vaccine efficacy against
any vulvar intraepithelial neoplasia grade I, vaginal
intraepithelial neoplasia grade I, or condyloma was
75% (22% to 94%) (4 v 16 cases), 48% (10% to 71%)
(21 v 41 cases), and 83% (74% to 89%) (29 v 169 cases)
respectively (table 5). Corresponding efficacy in the
intention to treat population was 32% (<0 to 60%) (27
v 40 cases), 31% (4% to 51%) (62 v 90 cases), and 62%
(54% to 69%) (134 v 351 cases), respectively (table 5).
DISCUSSION
We found that vaccination with quadrivalent HPV
vaccine had a high prophylactic efficacy against low
grade cervical and vulvovaginal neoplasias and condy-
loma attributed toHPV types 6, 11, 16, and 18 through
42 months of follow-up. This report confirms the
Table 3 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18):
analysis of intention to treat population*
Lesion and related HPV type†
Vaccine group Placebo group Vaccine efficacy (% (95% CI))
No of cases/
No of subjects
Person
years at risk
No of cases/
No of subjects
Person
years at risk Unadjusted Adjusted‡
Cervical intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 114/8562 29 611.9 366/8598 29 473.1 69.0 (61.6 to 75.1) 68.8§ (61.5 to 74.7)
HPV 6 or 11 19/8562 29 688.6 87/8598 29 648.7 78.2 (63.9 to 87.5) 78.0§ (63.9 to 86.6)
HPV 16 81/8562 29 652.9 240/8598 29 601.6 66.3 (56.5 to 74.1) 66.0§ (56.3 to 73.6)
HPV 18 20/8562 29 701.7 91/8598 29 672.7 78.0 (64.1 to 87.2) 78.1 (64.4 to 86.5)
Vulvar intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 8/8689 30 472.9 26/8702 30 563.7 69.1 (29.8 to 87.9) 69.1 (31.8 to 86.0)
HPV 6 or 11 8/8689 30 472.9 23/8702 30 570.7 65.1 (19.2 to 86.5) 65.1(22.0 to 84.4)
HPV 16 0/8689 30 490.8 6/8702 30 602.0 100 (<0 to 100) 100 (NA)
HPV 18 0/8689 30 488.1 0/8702 30 595.8 NA NA
Vaginal intraepithelial neoplasia grade I (HPV 6, 11, 16, 18): 4/8689 30 479.5 24/8702 30 568.6 83.3 (51.3 to 95.8) 83.3 (52.0 to 94.2)
HPV 6 or 11 2/8689 30 485.4 8/8702 30 599.2 74.9 (<0 to 97.4) 75.0 (<0 to 94.7)
HPV 16 2/8689 30 484.8 14/8702 30 590.1 85.7 (37.6 to 98.4) 85.7 (37.1 to 96.8)
HPV 18 1/8689 30 488.1 6/8702 30 595.8 83.3 (<0 to 99.6) 83.3 (<0 to 98.0)
Condyloma (HPV 6, 11, 16, 18): 63/8689 30 326.2 305/8702 30 137.9 79.5 (73.0 to 84.6) 79.4§ (73.0 to 84.3)
HPV 6 or 11 62/8689 30 328.7 298/8702 30 151.2 79.3 (72.7 to 84.5) 79.2§ (72.7 to 84.2)
HPV 16 3/8689 30 481.8 32/8702 30 564.2 90.6 (70.0 to 98.2) 90.4 (68.6 to 97.1)
HPV 18 1/8689 30 487.1 22/8702 30 571.0 95.4 (71.8 to 99.9) 95.3 (65.1 to 99.4)
*Intention to treat population=subjects who (a) received ≥1 vaccination; and (b) had any follow-up visit. Case counting began after day 1.
†A lesion attributable to vaccine HPV types was a diagnosed lesion with DNA from a vaccine HPV type detected in tissue from the same lesion. Cervical biopsies that were performed in the
absence of an abnormal cervical smear test result at the antecedent visit were excluded.
‡Adjusted by a Cox model using region and protocol (FUTURE I or FUTURE II) as covariates. Confidence intervals cannot be estimated in Cox models with zero cases in the vaccine group.
§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.
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results of previous studies with shorter follow-up times
and increases the statistical power of the efficacy esti-
mates (via longer follow-up) and provides evidence of
longer duration of protection. There were no signs of
waning protection.
Putting these data in context
The reported efficacy against low grade HPV related
lesions is important for several reasons. Firstly, these
lesions occur shortly after infection, and a reduction in
these lesions will be the earliest clinically noticeable
health gain to be realised by HPV vaccination. The
incubation time for condyloma is on average about
three months, and a decline in these readily apparent
lesions is an earlymonitoring end point for confirming
thatHPVvaccinationprogrammeshavehad an impor-
tant effect at the population level. Monitoring for out-
breaks with re-emergence of condylomas has been
proposed as an integral part of HPV surveillance pro-
grammes after vaccination.
Secondly, condyloma and cervical intraepithelial
neoplasia grade I occur at substantially higher rates
than cervical intraepithelial neoplasia grade II/III,
and the absolute number of these cases prevented by
vaccination is expected to be large when vaccine cov-
erage is high. Thus, short term benefits of HPV vacci-
nation in sexually active populations lie in the
reduction of condylomas and cervical intraepithelial
neoplasia grade I.
Thirdly, the fact that infection with multiple HPV
types is common in low grade disease, particularly in
cervical intraepithelial neoplasia but also in condy-
loma, has made it difficult to unequivocally assign
which of the HPV types present in a lesion are the cau-
sal infections. Our data therefore provide important
confirmatory evidence of the proportion of low grade
disease positive for HPV types 6, 11, 16, or 18 (37%
(366/984) of cervical intraepithelial neoplasia grade I,
87% (305/351) of condyloma (tables 3 and 5, intention
to treat placebo groups)). As expected, the proportion
of disease prevented in generally naive subjects was
similar but slightly lower than the proportion of cases
found to contain the DNA of these viruses (30% of cer-
vical intraepithelial neoplasia grade I, 83% of condy-
loma). Co-infection with a non-vaccine HPV type can
result in uncertainty in assigning causality, as shownby
the substantial proportion of the cases of disease in the
vaccine group that were also positive for a non-vaccine
HPV type (3/7 cases of cervical intraepithelial neopla-
sia grade I and 1/2 cases of condyloma in the per pro-
tocol population). In several cases the additional HPV
type had been detected at the baseline visit and per-
sisted through the study.
Low grade cervical and vulvovaginal lesions are
important fromapublic health perspective, as the diag-
nosis, follow-up, and treatment of these common
lesions are associated with substantial patient anxiety,
morbidity, and healthcare costs.10 24 The lifetime risk of
a clinically diagnosed condyloma has in Scandinavia
been estimated to be >10%.25 Management of cervical
intraepithelial neoplasia grade I and condyloma there-
fore contributes to a large proportion of the overall
financial burden of HPV related disease.26
Condyloma and HPV vaccination
The incidenceof condylomaand thepotential for health
gains by HPV vaccination has hitherto not been well
described. Although condyloma reporting systems are
used in a few countries, these systems have not been
sufficiently well controlled to allow reliable estimates
of incidence. In this studywemeasured vaccine efficacy
against disease related to specific HPV type and against
disease regardless of HPV type, enabling an estimate of
the total gains in reduced disease burden after vaccina-
tion of generally HPV naive women. In addition, our
report provides an estimate of the incidence of these
lesions in a carefully monitored cohort of women. We
found a high incidence of condyloma in the placebo
group (169 cases), which translates into a yearly inci-
dence of 1.0%. The vaccine efficacy against condyloma
Table 4 | Description of cases of low grade lesions attributable to human papillomavirus (HPV) types 6, 11, 16, or 18 among women in the per protocol
susceptible population receiving quadrivalent HPV vaccine
Case* Age (years)
Baseline HPV
positivity† Detected
Vaccine HPV
type found Patient narrative
Cervical intraepithelial neoplasia grade I
1 17 None Month 13 HPV 16 Colposcopy yielded two tissue specimens (both CIN grade I). Both biopsies were positive for HPV 58, one was
positive for HPV 16.
2 20 None Month 13 HPV 16 Colposcopy yielded two tissue specimens, one of which was CIN grade I positive for HPV 16
3 22 HPV18,31,33,
39
Month 11 HPV 16 Colposcopy yielded tissue specimen (read as CIN grade III) positive for HPV 18, 31, 33, and 39. Definitive
therapy by LEEP yielded seven biopsies, only one of which was positive for HPV 16 (also positive for HPV 18,
33, and 39) and diagnosed as CIN grade I
4 23 HPV 39 Month 13 HPV 16 Colposcopy yielded two tissue specimens, one was normal and one was CIN grade I positive for HPV 16
5 22 HPV 56 Month 35 HPV 18 Colposcopy tissue specimen read as CIN grade II (positive for HPV 56, negative for HPV 18). Three LEEP
specimens were diagnosed as CIN grade I (all positive for HPV 56, and 1 positive for HPV 18)
Condyloma
6 18 None Month 8 HPV 6
7 16 None Month 36 HPV 6 Condyloma positive for HPV 6 and 59
CIN=cervical intraepithelial neoplasia. LEEP=loop electrosurgical excision procedure.
*Narratives not available for two women who developed cervical intraepithelial neoplasia grade I.
†A positive test for DNA of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59.
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in generally HPV naive women of 83% thus corre-
sponds to a potential reduction in absolute yearly inci-
dence of condyloma of 0.83%.
In accordancewith previous reports, we foundonco-
genic HPV types such as HPV 16 and 18 in a propor-
tion of condylomas, but usually in conjunctionwith the
major HPV types associated with condyloma (types 6
and 11). Of the 190 cases of condyloma in the per pro-
tocol placebo group, 23 were associated with HPV
type 16, and 11 associated with HPV type 18. How-
ever, HPV types 6 or 11, or both, were also present in
all but four of these. Therefore, it seems likely that the
quadrivalent vaccine’s efficacy against condyloma is
primarily attributable to the HPV types 6 and 11 com-
ponents of the vaccine.
For cervical intraepithelial neoplasia grade I, HPV
type 16 was found in about twice as many cases (97/
6257) as HPV type 18 (47/7092) and types 6 or 11 (45/
6619). As multiple infection with several vaccine types
was not common, it seems reasonable to assume that
the vaccine’s HPV types 6 and 11 component contrib-
uted to about a quarter of the protective effect—that is,
about 7%-8% of all cervical intraepithelial neoplasia
grade I. Thus, the proportion of disease preventable
by vaccination againstHPV types 6 and 11was slightly
lower than the prevalence of types 6 or 11 in low grade
cervical and vulvovaginal disease (estimated at about
10% for cervical intraepithelial neoplasia grade I, 42%
for vulvar intraepithelial neoplasia grade I, and 90%
for condyloma1012 27 28). This observationmay possibly
be related to theoccasional cases thatmaybe causedby
co-infection with non-vaccine HPV types.
For vulvar intraepithelial neoplasia grade I, our data
support the International Society for the Study of Vul-
vovaginal Disease recommendation to rename this as a
“flat wart,” as all cases of vulvar intraepithelial neoplasia
grade I were found to harbour HPV types 6 or 11 and
thus had similar aetiology as other condylomas. For
vaginal intraepithelial neoplasia grade I, about equal
numbers of cases were infected with HPV types 6 or
11 as with HPV 16, but small numbers preclude more
exact estimationof theproportionof theprotective effect
against vaginal intraepithelial neoplasia that was attribu-
table to the HPV 6 and 11 component of the vaccine.
Regardless of whether vulvar or vaginal intraepithelial
neoplasia grade I are classified as precancerous or as
benign warts, patients presenting with low grade vulvar
or vaginal lesions still require clinical follow-up and, in
some cases, medical or surgical intervention.
Study limitations
Limitations of the current analyses include the fact that
the generally HPVnaive populationwas tested only for
thepresenceof the fourvaccineHPV types and10other
HPVtypesprevalent in cervical cancer.However, other
HPV types may contribute to condylomas, and there
are several uncommon HPV types that we did not test
for (such as HPV 68 and 73) that are classified as onco-
genic. Failure to identify infections with these types at
baseline would have resulted in an underestimation of
the protective effect against any disease in the generally
naive population. As these types are not common, this
conservative bias is not likely to be substantial. Another
limitation concerns the fact that rate estimates of disease
are dependent on the intensity of assessment. There
were some differences in assessment between studies,
notably the fact that protocol 015 required cervical
smear screening every 12 months, whereas protocol
013 required smear testing every six months. Although
the studies eligibility criteria included a limit on the life-
time number of sexual partners, the generalisability of
the results is probably high as the population studied
was enrolled globally.
Conclusions and policy implications
Quadrivalent HPV vaccination provided strong and
sustained protection for up to four years against con-
dyloma and low grade cervical and vulvovaginal neo-
plasia related to HPV types 6, 11, 16, and 18. The high
incidence of low grade disease seen in the placebo
group and the estimated benefits of vaccination on
total disease burden regardless of HPV type suggest
Table 5 | Efficacy of quadrivalent human papillomavirus (HPV) vaccine against low grade lesions attributable to any HPV type
No of cases/No of subjects Vaccine efficacy (% (95% CI))
Vaccine group Placebo group Unadjusted Adjusted*
Generally HPV naive population†
Cervical intraepithelial neoplasia grade I 241/4616 346/4680 29.7 (16.9 to 40.6) 29.9 (17.3 to 40.5)
Vulvar intraepithelial neoplasia grade I 4/4689 16/4735 74.7 (21.5 to 93.8) 74.6 (23.9 to 91.5)
Vaginal intraepithelial neoplasia grade I 21/4689 41/4735 48.1 (10.2 to 70.9) 49.2 (14.0 to 70.0)
Condyloma 29/4689 169/4735 82.8 (74.3 to 88.8) 82.8 (74.5 to 88.4)
Intention to treat population‡
Cervical intraepithelial neoplasia grade I 788/8562 984/8598 20.3 (12.4 to 27.5) 20.0 (12.1 to 27.2)
Vulvar intraepithelial neoplasia grade I 27/8689 40/8702 32.3 (<0 to 60.0) 32.1 (<0 to 58.4)
Vaginal intraepithelial neoplasia grade I 62/8689 90/8702 30.9 (3.5 to 50.8) 31.2 (4.9 to 50.2)
Condyloma 134/8689 351/8702 62.0 (53.5 to 69.1) 61.9§ (53.5 to 68.8)
*Vaccine efficacy was adjusted by a Cox model using region and protocol (FUTURE I and FUTURE II) as covariates.
†Generally HPV naive population=subjects who (a) received ≥1 vaccination; (b) tested negative at day 1 for vaccine HPV types (6, 11, 16, and 18) by
serology and polymerase chain reaction (PCR) and for non-vaccine, high risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) by PCR and had
a negative cervical smear test on day 1; and (c) had any follow-up visit. Case counting began after day 1.
‡Intention to treat population=subjects who (a) received ≥1 vaccination; and (b) had any follow-up visit. Case counting began after day 1.
§Proportional hazard assumption was violated for the treatment effect. The vaccine efficacy was reported as average effect.
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that an important portion of the clinical benefit seen in
the early years after deployment of the quadrivalent
HPV vaccine will be through reductions of cervical
intraepithelial neoplasia grade I and condyloma.
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